EUVIMEDEUVIMED entdecken
Open Access

Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood–Brain Barrier

Andrew L Zhou iD, Suresh K Swaminathan, Vrishali S Salian, Lushan Wang, Geoffry L Curran, Hoon-Ki Min, Val J Lowe, Karunya K Kandimalla iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.3c00784 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Andrew L Zhou und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics and Brain Barriers Research Center, University of Minnesota College of Pharmacy, Minneapolis, Minnesota 55455, United Sta…. Hauptthemen laut MEDLINE: Amyloid beta-Peptides, Blood-Brain Barrier, Insulin, Signal Transduction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The blood-brain barrier (BBB) is instrumental in clearing toxic metabolites from the brain, such as amyloid-β (Aβ) peptides, and in delivering essential nutrients to the brain, like insulin. In Alzheimer's disease (AD) brain, increased Aβ levels are paralleled by decreased insulin levels, which are accompanied by insulin signaling deficits at the BBB. Thus, we investigated the impact of insulin-like growth factor and insulin receptor (IGF1R and IR) signaling on Aβ and insulin trafficking at the BBB. Following intravenous infusion of an IGF1R/IR kinase inhibitor (AG1024) in wild-type mice, the BBB trafficking of 125I radiolabeled Aβ peptides and insulin was assessed by dynamic SPECT/CT imaging. The brain efflux of [125I]iodo-Aβ42 decreased upon AG1024 treatment. Additionally, the brain influx of [125I]iodoinsulin, [125I]iodo-Aβ42, [125I]iodo-Aβ40, and [125I]iodo-BSA (BBB integrity marker) was decreased, increased, unchanged, and unchanged, respectively, upon AG1024 treatment. Subsequent mechanistic studies were performed using an in vitro BBB cell model. The cell uptake of [125I]iodoinsulin, [125I]iodo-Aβ42, and [125I]iodo-Aβ40 was decreased, increased, and unchanged, respectively, upon AG1024 treatment. Further, AG1024 reduced the phosphorylation of insulin signaling kinases (Akt and Erk) and the membrane expression of Aβ and insulin trafficking receptors (LRP-1 and IR-β). These findings reveal that insulin signaling differentially regulates the BBB trafficking of Aβ peptides and insulin. Moreover, deficits in IGF1R and IR signaling, as observed in the brains of type II diabetes and AD patients, are expected to increase Aβ accumulation while decreasing insulin delivery to the brain, which has been linked to the progression of cognitive decline in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid beta-PeptidesBlood-Brain BarrierInsulinSignal TransductionAnimalsMaleMiceAlzheimer DiseaseBrainIodine RadioisotopesMice, Inbred C57BLPeptide FragmentsReceptor, IGF Type 1Receptor, InsulinSingle Photon Emission Computed Tomography Computed TomographyTyrphostins

Stichwörter der Autor:innen

Alzheimer’s diseaseamyloid-betablood–brain barrierinsulintransport

Substanzen

Amyloid beta-PeptidesIgf1r protein, mouseInsulinIodine RadioisotopesPeptide FragmentsReceptor, IGF Type 1Receptor, Insulintyrphostin AG 1024Tyrphostins

Autor:innen und Institutionen

  • Department of Pharmaceutics and Brain Barriers Research Center, University of Minnesota College of Pharmacy, Minneapolis, Minnesota 55455, United States.
  • Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, United States.
  • Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, United States.

ORCID-Profile: Andrew L Zhou, Karunya K Kandimalla

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • Minnesota Partnership for Biotechnology and Medical Genomics

Zitieren

APA

Zhou, A. L., Swaminathan, S. K., Salian, V. S., Wang, L., Curran, G. L., Min, H. K., Lowe, V. J., & Kandimalla, K. K. (2024). Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood–Brain Barrier. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00784

Vancouver

Zhou AL, Swaminathan SK, Salian VS, Wang L, Curran GL, Min HK, et al. Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood–Brain Barrier. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c00784

BibTeX
@article{Zhou2024,
  author = {Zhou, Andrew L and Swaminathan, Suresh K and Salian, Vrishali S and Wang, Lushan and Curran, Geoffry L and Min, Hoon-Ki and Lowe, Val J and Kandimalla, Karunya K},
  title = {Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood–Brain Barrier},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.3c00784}
}
Kostenlos starten →